Junevity Raises $10M to Power the Future of Longevity with AI-Driven siRNA Therapeutics

Junevity is proud to announce a successful funding round of $10,000,000, a monumental milestone that propels our mission to extend human lifespan and healthspan even further. Founded out of UCSF in 2023, Junevity has rapidly emerged as a pioneering force in the realm of longevity biotechnology. Our breakthrough innovation, the Cell Reset therapeutics program, represents a new class of medicines designed to reverse transcriptional damage with siRNA. By harnessing the power of our revolutionary RESET Platform—the first platform of its kind to integrate large-scale human data and artificial intelligence—we are charting a transformative path in the development of novel siRNA therapeutics that target transcription factors. This latest investment will fuel critical research and development efforts that move our technology closer to clinical applications. Our goal is not only to set new benchmarks in longevity science but also to redefine how we approach age-related diseases and overall human health. The infusion of capital empowers us to expand our research teams, accelerate technology platforms, and forge strategic partnerships with leading academic institutions and industry innovators. With robust support from our investors, we reaffirm our commitment to exploring uncharted territories in biomedicine, where the reversal of cellular damage could change the narrative of aging. We believe that extending human healthspan is as important as extending lifespan, and this funding will help us inch closer to a future where age is just a number. Junevity is enthusiastic about the path ahead and remains dedicated to unleashing groundbreaking treatments that have the potential to revolutionize the way we understand and treat the aging process.